Impact of siponimod on vaccination response in a randomized, placebo-controlled study.

Ufer, Mike; Shakeri-Nejad, Kasra; Gardin, Anne; Su, Zhenzhong; Paule, Ines; Marbury, Thomas C; Legangneux, Eric

Ufer, Mike; Shakeri-Nejad, Kasra; Gardin, Anne; Su, Zhenzhong; Paule, Ines; Marbury, Thomas C; Legangneux, Eric.

Afiliación

Ufer M; Novartis Pharma AG (M.U., K.S.-N., A.G., Z.S., I.P., E.L.), Basel, Switzerland; and Orlando Clinical Research Center (T.C.M.), Orlando, FL.
Shakeri-Nejad K; Novartis Pharma AG (M.U., K.S.-N., A.G., Z.S., I.P., E.L.), Basel, Switzerland; and Orlando Clinical Research Center (T.C.M.), Orlando, FL.
Gardin A; Novartis Pharma AG (M.U., K.S.-N., A.G., Z.S., I.P., E.L.), Basel, Switzerland; and Orlando Clinical Research Center (T.C.M.), Orlando, FL.
Su Z; Novartis Pharma AG (M.U., K.S.-N., A.G., Z.S., I.P., E.L.), Basel, Switzerland; and Orlando Clinical Research Center (T.C.M.), Orlando, FL.
Paule I; Novartis Pharma AG (M.U., K.S.-N., A.G., Z.S., I.P., E.L.), Basel, Switzerland; and Orlando Clinical Research Center (T.C.M.), Orlando, FL.
Marbury TC; Novartis Pharma AG (M.U., K.S.-N., A.G., Z.S., I.P., E.L.), Basel, Switzerland; and Orlando Clinical Research Center (T.C.M.), Orlando, FL.
Legangneux E; Novartis Pharma AG (M.U., K.S.-N., A.G., Z.S., I.P., E.L.), Basel, Switzerland; and Orlando Clinical Research Center (T.C.M.), Orlando, FL.

Neurol Neuroimmunol Neuroinflamm ; 4(6): e398, 2017 Nov.

Article en En | MEDLINE | ID: mdl-28955715

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Neurol Neuroimmunol Neuroinflamm Año: 2017 Tipo del documento: Article